Bio-Path Holdings Overview
Bio-Path Holdings (BPTH) has a ROE of 42.64%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow42.64%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Bio-Path Holdings posts a ROE of 42.64%. That is above the Healthcare sector average of -100.59%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near -100.59% is typical. Bio-Path Holdings's 42.64% is higher that level. That is roughly 142.4% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Bio-Path Holdings's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 42.64%; use YoY and peer views to separate noise from signal.
Context for BPTH's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -100.59%), and (3) consistency with growth and profitability. This page covers the first two; Bio-Path Holdings's other metric pages and overview cover the third.
Judging Bio-Path Holdings against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 42.64% here, then scan peer and history charts to see if the gap is persistent.
